This study sought to investigate whether the beneficial impact of high-dose rosuvastatin against contrast-induced acute kidney injury ( CI-AKI ) in acute coronary syndrome ( ACS ) patients varied in relation to baseline high-sensitivity C-reactive protein ( hs-CRP ) levels .